古塞奇尤单抗治疗所有肤色中重度银屑病:VISIBLE随机临床试验A队列
VISIBLE研究A队列纳入肤色人种中重度银屑病患者,评估古塞奇尤单抗100 mg治疗48周的疗效与安全性。第16周,古塞奇尤单抗组IGA 0/1和PASI 90应答率显著优于安慰剂组。疗效持续至第48周,生活质量与症状评分显著改善。
要点
- 第16周古塞奇尤单抗组IGA 0/1达74.0%,PASI 90达57.1%,均显著优于安慰剂。
- 第16周DLQI和PSSD症状评分较基线显著改善,瘙痒应答率66.7%。
- 疗效持续至第48周,PASI和BSA平均改善超94%,超50%患者完全清除。
核心结论
- 古塞奇尤单抗治疗肤色人种中重度银屑病,第16周即显示显著皮肤清除和生活质量改善,并持续至第48周。
研究设计与样本
- 正在进行的3b期随机临床试验,在美国和加拿大39个中心开展,纳入103例肤色人种中重度银屑病成人患者。
- 参与者按3:1随机接受古塞奇尤单抗100 mg(77例)或安慰剂(26例),安慰剂组第16和20周交叉至古塞奇尤单抗。
- 数据收集时间为2022年8月至2024年6月,94例(91.3%)完成48周治疗。
主要发现
- 第16周,古塞奇尤单抗组 vs 安慰剂组:IGA 0/1为57/77(74.0%) vs 0/26(P < .001);PASI 90为44/77(57.1%) vs 1/26(3.8%)(P < .001)。
- 第16周,IGA 0为25/77(32.5%) vs 0/26(P < .001);PASI 100为23/77(29.9%) vs 0/26(P = .002)。
- 第16周,DLQI least-squares mean变化为-12.1(95% CI, -13.1 to -10.9) vs -2.5(95% CI, -4.4 to -0.6)(P < .001);PSSD症状评分变化为-49.4(95% CI, -54.0 to -44.9) vs -8.2(95% CI, -15.8 to -0.6)(P < .001)。
- 基线PSSD瘙痒评分≥4者中,第16周瘙痒评分降低≥4分的比例为48/72(66.7%) vs 4/24(16.7%)(P < .001)。
- 截至第48周,古塞奇尤单抗随机组PASI和BSA平均改善百分比均超过94%,超过50%的参与者达到完全清除。
关键数值与推荐
- 纳入标准:肤色人种,中重度银屑病,BSA ≥10%,PASI ≥12,IGA ≥3。
- 共同主要终点:第16周IGA 0/1和PASI 90(古塞奇尤单抗 vs 安慰剂)。
- 主要次要终点包括IGA 0、PASI 100、PASI和BSA百分比变化、DLQI和PSSD症状变化、PSSD瘙痒评分降低≥4分。
临床怎么用
- 对于肤色人种中重度银屑病患者,古塞奇尤单抗100 mg(第0、4周,随后每8周)可显著改善皮肤清除和生活质量。
- 治疗16周即可观察到显著疗效,并持续至48周,支持长期使用。
局限性
- 样本量较小(共103例),可能影响结果的普遍性。
- 研究仅纳入美国和加拿大中心,地区外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Data and educational gaps in populations with skin of color contribute to racial and ethnic disparities in psoriasis treatment. Cohort A of the VISIBLE study includes participants with psoriasis who self-identify as belonging to a racial or ethnic category other than White, across the entire skin-tone spectrum. OBJECTIVE: To evaluate efficacy, quality of life, and adverse event outcomes among participants with moderate to severe psoriasis and skin of color who received guselkumab, 100 mg, for up to 48 weeks. DESIGN, SETTING, AND PARTICIPANTS: This ongoing phase 3b, randomized clinical trial at 39 sites in the US and Canada enrolled adults with skin of color and moderate to severe psoriasis (body surface area [BSA] ≥10%; Psoriasis Area and Severity Index [PASI] ≥12; Investigator's Global Assessment [IGA] ≥3). Data were collected from August 2022 to June 2024. INTERVENTIONS: Randomized participants (3:1) received guselkumab, 100 mg, at weeks 0 and 4, then every 8 weeks, or placebo with crossover to guselkumab at weeks 16 and 20, then every 8 weeks. MAIN OUTCOMES AND MEASURES: Coprimary end points were IGA score of 0 or 1 (IGA 0/1) and PASI improvement of 90% or more (PASI 90) at week 16 (guselkumab vs placebo). Major secondary end points included IGA 0; PASI 100; percentage changes from baseline in PASI and BSA; changes from baseline in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) symptoms; and at least a 4-point reduction in PSSD itch. RESULTS: Of 103 participants (77 randomized to guselkumab; 26 randomized to placebo), 94 (91.3%) completed 48 weeks of treatment. The mean (SD) age overall was 44.1 (12.9) years, and 74 participants (71.8%) were male. At week 16, coprimary end points were achieved by greater proportions of guselkumab- vs placebo-treated participants (IGA 0/1: 57 of 77 [74.0%] vs 0 of 26; P < .001; PASI 90: 44 of 77 [57.1%] vs 1 of 26 [3.8%]; P < .001); 25 of 77 (32.5%) vs 0 of 26 achieved IGA 0 (P < .001), and 23 of 77 (29.9%) vs 0 of 26 achieved PASI 100 (P = .002). DLQI and PSSD symptoms score least-squares mean changes from baseline were -12.1 (95% CI, -13.1 to -10.9) vs -2.5 (95% CI, -4.4 to -0.6) (P < .001), and -49.4 (95% CI, -54.0 to -44.9) vs -8.2 (95% CI, -15.8 to -0.6) (P < .001), respectively. A 4-point or greater reduction in PSSD itch score was achieved by 48 (66.7%) vs 4 (16.7%) participants with a baseline score of at least 4 (P < .001). Efficacy increased and was maintained through week 48, with guselkumab-randomized participants achieving mean percentage improvements in PASI and BSA of more than 94%, and more than 50% of participants achieving complete clearance. Infections were the most common adverse events in the guselkumab (16 [20.8%]) and placebo (3 [11.5%]) groups through week 16, predominantly upper respiratory tract infection and nasopharyngitis. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, after 3 doses of guselkumab, significant skin clearance and quality of life improvements were observed in this cohort of participants with moderate to severe psoriasis and skin of color across the range of objectively measured skin tones. Improvements increased and were maintained through week 48. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05272150.
引用
- Alexis A, McMichael A, Soung J, et al. Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial. JAMA Dermatol. 2025. PMID: 40560559. doi:10.1001/jamadermatol.2025.1836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。